Roberta Zappasodi

15.2k citations

56 papers · 2.9k indexed · 4 hit papers · h-index 24

Impact in

Immunology top 1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
- T-cell and B-cell Immunology
Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research

Papers in

Immunology 43
- Immunotherapy and Immune Responses 28
- Immune Cell Function and Interaction 17
- T-cell and B-cell Immunology 8
- Immune cells in cancer 8
Oncology 35
- Cancer Immunotherapy and Biomarkers 27
- CAR-T cell therapy research 16

Co-authors: Taha Merghoub Jedd D. Wolchok Alexander C. Huang Massimo Di Nicola Sadna Budhu Cailian Liu Alessandro M. Gianni Carmelo Carlo‐Stella
Journals: Cancer Research (9 papers)Blood (6 papers)Cancer Immunology Research (3 papers)Journal for ImmunoTherapy of Cancer (3 papers)Clinical Cancer Research (2 papers)
Partner nations: United States Italy Switzerland

In The Last Decade

Roberta Zappasodi

55 papers receiving 2.8k citations

Hit Papers

align trajectories log scale

A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance 2022 · 364 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Nature Immunology
2020 Nature Communications
2020 Nature Immunology
2018 Cancer Cell

Peers

Countries citing papers authored by Roberta Zappasodi

Since Specialization

Citations

This map shows the geographic impact of Roberta Zappasodi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberta Zappasodi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberta Zappasodi more than expected).

Fields of papers citing papers by Roberta Zappasodi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberta Zappasodi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberta Zappasodi. The network helps show where Roberta Zappasodi may publish in the future.

Co-authors

The 25 scholars most cited alongside Roberta Zappasodi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Roberta Zappasodi Line = papers co-authored together Roberta Zappasodi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors Clinical Cancer Research ·Omid Hamid, Dana B. Cardin, F. Stephen Hodi, Patricia LoRusso, Taha Merghoub, Roberta Zappasodi, Rachana Maniyar, John E. Janik, Manfred Velden, Feng Zhou, Zhiwan Dong, Xuejun Chen, James J. Harding	2025	0
2	Modulating Treg stability to improve cancer immunotherapy Trends in cancer ·Jee Hye Kang, Roberta Zappasodi	2023	81
3	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors Journal for ImmunoTherapy of Cancer ·Harriet M. Kluger, J. Carl Barrett, Justin F. Gainor, Omid Hamid, Michael E. Hurwitz, Theresa LaVallee, Rebecca A. Moss, Roberta Zappasodi, Ryan J. Sullivan, Hussein A. Tawbi, Elad Sharon	2023	40
4	Targeting GITR in cancer immunotherapy - there is no perfect knowledge Oncotarget ·Diwakar Davar, Roberta Zappasodi	2023	12
5	APR-246 increases tumor antigenicity independent of p53 Life Science Alliance ·Judith Michels, Divya Venkatesh, Cailian Liu, Sadna Budhu, Hong Zhong, Mariam M. George, Daniel Thach, Zhong‐Ke Yao, Ouathek Ouerfelli, Hengrui Liu, Brent R. Stockwell, Luís Felipe Campesato, Dmitriy Zamarin, Roberta Zappasodi, Jedd D. Wolchok, Taha Merghoub	2023	4
6	1444 Pharmacologic LDH inhibition redirects intratumoral glucose consumption and improves response to CTLA-4 blockade SHILAP Revista de lepidopterología ·Svena Verma, Roberta Zappasodi, Sadna Budhu, Inna Serganova, Lauren Dong, Levi Mangarin, Yacine Marouf, Jonathan F. Khan, Jedd D. Wolchok, Taha Merghoub	2023	1
7	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors Clinical Cancer Research ·Diwakar Davar, Roberta Zappasodi, Hong Wang, Girish S. Naik, Takami Sato, Todd M. Bauer, David L. Bajor, Olivier Rixe, Walter Newman, Jingjing Qi, Aliya Holland, Phillip Wong, Lianna Sifferlen, Diane Piper, Cynthia A. Sirard, Taha Merghoub, Jedd D. Wolchok, Jason J. Luke	2022	37
8	Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma Cell Reports ·Sadna Budhu, Rachel Giese, Aditi Gupta, Kelly Fitzgerald, Roberta Zappasodi, Sara Schad, Daniel Hirschhorn, Luís Felipe Campesato, Olivier De Henau, Mathieu Gigoux, Cailian Liu, Gregory Mazo, Liang Deng, Christopher A. Barker, Jedd D. Wolchok, Taha Merghoub	2021	31
9	619 Pharmacologic modulation of tumor glycolysis to improve responses to immune checkpoint blockade therapy SHILAP Revista de lepidopterología ·Svena Verma, Rachana Maniyar, Myat Ko, Sadna Budhu, Inna Serganova, Roberta Zappasodi, Ronald Blasberg, Taha Merghoub, Jedd D. Wolchok, Levi Mangarin	2021	2
10	Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine Nature Communications ·Luís Felipe Campesato, Sadna Budhu, Jeremy H. Tchaicha, Chien‐Huan Weng, Mathieu Gigoux, Ivan Cohen, David Redmond, Levi Mangarin, Stephane Pourpe, Cailian Liu, Roberta Zappasodi, Dmitriy Zamarin, Jill Cavanaugh, Alfredo Castro, Mark Manfredi, Karen McGovern, Taha Merghoub, Jedd D. Wolchok Hit paper breakdown →	2020	335
11	In vitro assays for effector T cell functions and activity of immunomodulatory antibodies Methods in enzymology on CD-ROM/Methods in enzymology ·Roberta Zappasodi, Sadna Budhu, Mohsen Abu-Akeel, Taha Merghoub	2020	10
12	CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors Nature Immunology ·Haiping Wang, Fabien Franco, Yao-Chen Tsui, Xin Xie, Marcel P. Trefny, Roberta Zappasodi, Syed Raza Mohmood, Juan Fernández-García, Chin-Hsien Tsai, Isabell Schulze, Florence Picard, Etienne Meylan, Roy L. Silverstein, Ira J. Goldberg, Sarah‐Maria Fendt, Jedd D. Wolchok, Taha Merghoub, Camilla Jandus, Alfred Zippelius, Ping‐Chih Ho Hit paper breakdown →	2020	477
13	Non-conventional Inhibitory CD4+Foxp3−PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity Cancer Cell ·Roberta Zappasodi, Sadna Budhu, Matthew D. Hellmann, Michael A. Postow, Yasin Şenbabaoğlu, Sasikanth Manne, Billel Gasmi, Cailian Liu, Hong Zhong, Yanyun Li, Alexander C. Huang, Daniel Hirschhorn-Cymerman, Katherine S. Panageas, E. John Wherry, Taha Merghoub, Jedd D. Wolchok	2018	113
14	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies Cancer Cell ·Roberta Zappasodi, Taha Merghoub, Jedd D. Wolchok Hit paper breakdown →	2018	418
15	Immunotherapy advances in uro-genital malignancies Critical Reviews in Oncology/Hematology ·Raffaele Ratta, Roberta Zappasodi, Daniele Raggi, Paolo Grassi, Elena Verzoni, Andrea Necchi, Massimo Di Nicola, Roberto Salvioni, Filippo de Braud, Giuseppe Procopio	2016	20
16	Combination of Alphavirus Replicon Particle–Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates Cancer Immunology Research ·Francesca Avogadri, Roberta Zappasodi, Arvin Yang, Sadna Budhu, Nicole Malandro, Daniel Hirschhorn-Cymerman, Shakuntala Tiwari, Maureen F. Maughan, Robert A. Olmsted, Jedd D. Wolchok, Taha Merghoub	2014	36
17	Sialidase NEU4 is involved in glioblastoma stem cell survival Cell Death and Disease ·Ilaria Silvestri, Francesca Testa, Roberta Zappasodi, Christopher W. Cairo, Yanbo Zhang, Barbara Lupo, Rossella Galli, Massimo Di Nicola, Bruno Venerando, Cristina Tringali	2014	25
18	Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab Cancer Research ·Lorenzo Castagnoli, Manuela Iezzi, Gaia C. Ghedini, Valentina Ciravolo, Giulia Marzano, Alessia Lamolinara, Roberta Zappasodi, Patrizia Gasparini, Manuela Campiglio, Augusto Amici, Claudia Chiodoni, Arianna Palladini, Pier‐Luigi Lollini, Tiziana Triulzi, Sylvie Ménard, Patrizia Nanni, Elda Tagliabue, Serenella M. Pupa	2014	58
19	Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic Melanoma Cancer Research ·Andrea Anichini, Alessandra Molla, Claudia Vegetti, Ilaria Bersani, Roberta Zappasodi, Flavio Arienti, Fernando Ravagnani, Andrea Maurichi, Roberto Patuzzo, Mario Santinami, Hanspeter Pircher, Massimo Di Nicola, Roberta Mortarini	2010	38
20	Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death Cancer Research ·Roberta Zappasodi, Serenella M. Pupa, Gaia C. Ghedini, Italia Bongarzone, Michele Magni, Antonello D. Cabras, Mario P. Colombo, Carmelo Carlo‐Stella, Alessandro M. Gianni, Massimo Di Nicola	2010	114

About Roberta Zappasodi

Roberta Zappasodi is a scholar working on Immunology, Oncology, Cancer Research, Physiology and Biological Psychiatry, having authored 56 papers that have together received 2.9k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (28 papers), Cancer Immunotherapy and Biomarkers (27 papers), Immune Cell Function and Interaction (17 papers), CAR-T cell therapy research (16 papers), Cancer, Hypoxia, and Metabolism (9 papers), T-cell and B-cell Immunology (8 papers), Immune cells in cancer (8 papers) and Lymphoma Diagnosis and Treatment (4 papers). The work is most often cited by research in Immunology (1.6k citations), Oncology (1.5k citations), Biological Psychiatry (110 citations), Cancer Research (459 citations) and Molecular Biology (877 citations). Roberta Zappasodi has collaborated with scholars based in United States, Italy and Switzerland. Frequent co-authors include Taha Merghoub, Jedd D. Wolchok, Alexander C. Huang, Massimo Di Nicola, Sadna Budhu, Cailian Liu, Alessandro M. Gianni, Carmelo Carlo‐Stella, Serenella M. Pupa and Isabell Schulze. Their work appears in journals such as Cancer Research, Blood, Cancer Immunology Research, Journal for ImmunoTherapy of Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact